AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform

AstraZeneca’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks Consensus Estimate. Core earnings of $2.17 per share rose 10% year over year on a reported basis and 12% on a constant exchange rate (CER).Total revenues of $14.46 billion rose 12%...